Anna Deleskog
AstraZeneca
3 Papers
34 Citations
Anna Deleskog is an academic researcher from AstraZeneca. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study
Cengiz Özcan,Anna Deleskog,Anne Marie Schjerning Olsen,Helene Nordahl Christensen,Morten Lock Hansen,Gunnar Gislason +5 more
TL;DR: Despite contemporary treatment at baseline, stable post-MI patients’ 4-year outcome was similar to 1- year outcome after MI, and CAD severity remained a critical risk factor the first year and thereafter.
50
Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland.
Tuire Prami,Houssem Khanfir,Anna Deleskog,Pål Hasvold,Ville Kytö,Eeva Reissell,Juhani Airaksinen +6 more
TL;DR: Only half of the patients with ACS received guideline-recommended ADP receptor-inhibiting OAP treatment after hospital discharge, suggesting suboptimal treatment practices.
40
Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.
TL;DR: Among DAPT-treated patients, ticagrelor has emerged as the preferred P2Y12 antagonist in patients undergoing angiography, whereas clopidogrel tended to be prescribed to patients treated non-invasively.
40